Becton Dickinson (BDX)
NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-07-07
$156.30+0.49%
Close 2026-07-07 · 1-day change
Reading BDX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BDX free→NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-07-07
Reading BDX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BDX free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on healthcare. The current thesis state is intact, as recent financial performance has been strong, although management execution has shown volatility.
The valuation is considered expensive compared to peers, with a premium of 0.36. The market seems to have priced in a justified level of performance, but there is a slight expectations gap.
Fundamentals are likely to remain stable, given the strong recent performance. However, there is a moderate risk due to the potential for management to miss guidance, which could impact credibility.
The thesis hinges on the performance of sector bellwethers like ISRG, MDLN, and RMD. If these companies continue to perform well, it could support BDX's growth, while any negative shifts could pose risks.
Overall, BDX's position is supported by strong recent results but is sensitive to sector dynamics and management execution. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The positive outlook on the spin-off of Biosciences and Diagnostics suggests a more streamlined business with potential for mid-to-high teens returns. There are no current threats identified that would weaken this view.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The merger is expected to create a larger market presence and drive revenue growth.
Confirms:BD reports revenue growth above mid-to-high single digits in the next earnings.
Disproves:Revenue growth drops below the expected mid-to-high single digits in the next earnings.
Why it matters: Getting regulatory approval is key for the Waters merger. It affects future growth.
Confirms one read:The company got the green light for the Waters merger.
Confirms the other:There is a delay or no approval for the Waters merger.
Why it matters: Earnings results will show BD's financial health after the spin-off and merger.
Confirms one read:Q2 earnings are better than what analysts expected. This shows strong performance.
Confirms the other:Q2 earnings are worse than what analysts expected. This raises concerns about growth.
Why it matters: Paying off debt can make the balance sheet stronger. It can also help financial stability.
Confirms:The company paid off a lot of debt with the $4 billion cash.
Disproves:There is no big debt repayment or increase in debt levels.
Why it matters: Paying down debt can strengthen BD's balance sheet and improve financial health.
Confirms:BD says it has reduced debt after the $4 billion cash distribution.
Disproves:Debt levels stay the same or go up after the cash distribution.
Why it matters: The buyback program shows BD wants to give value back to shareholders.
Confirms:BD completes the $2 billion share repurchase program as planned.
Disproves:The share repurchase program is delayed or cut back a lot.
Why it matters: Naming a new president can show stability in leadership and future plans.
Confirms one read:BD names a new president before the current one retires.
Confirms the other:No news on a new president before the current one retires.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.